David R. Bonsall
YOU?
Author Swipe
View article: Geospatial and phylogenetic clustering of acute and recent HIV infections in Lilongwe, Malawi
Geospatial and phylogenetic clustering of acute and recent HIV infections in Lilongwe, Malawi Open
HIV transmission during early HIV infection impedes efforts to end HIV as a public health threat, as diagnosis typically occurs after this period of elevated transmission risk. To guide diagnosis and prevention strategies, we evaluated the…
View article: HIV drug resistance during antiretroviral therapy scale-up in Uganda, 2012–19: a population-based, longitudinal study
HIV drug resistance during antiretroviral therapy scale-up in Uganda, 2012–19: a population-based, longitudinal study Open
National Institutes of Health, Johns Hopkins University Center for AIDS Research, Bill & Melinda Gates Foundation, and the US Centers for Disease Control and Prevention.
View article: Patterns of HIV-1 viral load suppression and drug resistance during the dolutegravir transition: a population-based longitudinal study
Patterns of HIV-1 viral load suppression and drug resistance during the dolutegravir transition: a population-based longitudinal study Open
Background Data on the population-scale impact of dolutegravir (DTG)-based HIV regimens in sub-Saharan Africa are extremely limited. We used data from a surveillance cohort in southern Uganda to assess viral suppression and antiretroviral …
View article: Preclinical <i>in vitro</i> and <i>in vivo</i> evaluation of [ <sup>11</sup> C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates
Preclinical <i>in vitro</i> and <i>in vivo</i> evaluation of [ <sup>11</sup> C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates Open
This paper describes the preclinical validation of the radioligand [ 11 C]ORM-13070 and its tritiated analog for addressing selectivity and occupancy of the selective alpha-2C adrenergic receptor (α 2C R) antagonist BAY 292 in the cynomolg…
View article: Correction: Sub-Chronic Ketamine Administration Increases Dopamine Synthesis Capacity in the Mouse Midbrain: a Preclinical In Vivo PET Study
Correction: Sub-Chronic Ketamine Administration Increases Dopamine Synthesis Capacity in the Mouse Midbrain: a Preclinical In Vivo PET Study Open
View article: Sub-Chronic Ketamine Administration Increases Dopamine Synthesis Capacity in the Mouse Midbrain: a Preclinical In Vivo PET Study
Sub-Chronic Ketamine Administration Increases Dopamine Synthesis Capacity in the Mouse Midbrain: a Preclinical In Vivo PET Study Open
View article: Sub-chronic ketamine administration increases dopamine synthesis capacity in the midbrain: a preclinical in vivo pet study
Sub-chronic ketamine administration increases dopamine synthesis capacity in the midbrain: a preclinical in vivo pet study Open
View article: Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine
Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine Open
View article: O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS
O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS Open
Background The synaptic dysfunction hypothesis of schizophrenia is supported by multiple lines of evidence. However, in vivo evidence is lacking. Moreover, it is not known if antipsychotics alter synaptic protein levels. We addressed this …
View article: Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats
Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats Open
Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis, but this has not been tested directly in vivo. Here, we investigated synaptic vesicle glycoprotein 2A (SV2A) levels and their relationship to symptoms a…
View article: Mesocorticolimbic circuit mechanisms underlying the effects of ketamine on dopamine: a translational imaging study
Mesocorticolimbic circuit mechanisms underlying the effects of ketamine on dopamine: a translational imaging study Open
Patients with schizophrenia show increased striatal dopamine synthesis capacity in imaging studies. However, the mechanism underlying this is unclear but may be due to N-methyl-D-aspartate receptor (NMDAR) hypofunction and parvalbumin (PV)…
View article: Alterations in glutamatergic signaling contribute to the decline of circadian photoentrainment in aged mice
Alterations in glutamatergic signaling contribute to the decline of circadian photoentrainment in aged mice Open
Robust physiological circadian rhythms form an integral part of well-being. The aging process has been found to negatively impact systems that drive circadian physiology, typically manifesting as symptoms associated with abnormal/disrupted…
View article: Effect of supramaximal loaded resistance exercise on post-activation potentiation in university rugby union players
Effect of supramaximal loaded resistance exercise on post-activation potentiation in university rugby union players Open
Purpose – This study aimed to assess whether a supramaximal loaded squat using variable resistance can enhance countermovement jump (CMJ) performance via Post-activation Potentiation (PAP) to a greater degree than using traditional metho…
View article: Suppression of Locomotor Activity in Female C57Bl/6J Mice Treated with Interleukin-1β: Investigating a Method for the Study of Fatigue in Laboratory Animals
Suppression of Locomotor Activity in Female C57Bl/6J Mice Treated with Interleukin-1β: Investigating a Method for the Study of Fatigue in Laboratory Animals Open
Fatigue is a disabling symptom in patients with multiple sclerosis and Parkinson's Disease, and is also common in patients with traumatic brain injury, cancer, and inflammatory disorders. Little is known about the neurobiology of fatigue, …